Baz Biomedical, a Developer of Needle-Free Drug Delivery Devices, Successfully Completes 2022 IR

Baz Biomedical, the world’s first developer of a solenoid-based needle-free drug delivery device, successfully completed its 2022 IR.

Baz Biomedical received a total investment of 5.2 billion KRW, with 2.8 billion KRW in September and 2.4 billion KRW in December, from institutional investors including Hanwha Investment & Securities, as well as individual investors composed of domestic doctors and patent attorneys.

Park Ki-sung, CEO of Golden Wise Doctors, who successfully led this investment, explained, “In today’s challenging investment environment, Baz Biomedical’s world-first solenoid-based drug delivery technology and medical device ‘CureJet’ & beauty device ‘NovoJet’ have been recognized as core K-medical devices with potential for global market entry.”

CEO Park Ki-sung personally visited existing follower investors and new user doctors to conduct IR and demos, proving the excellence of Baz Biomedical’s products firsthand.

In particular, the participation of patent attorneys from Hanyang Patent Corporation, one of the top five patent law firms in Korea, is a significant endorsement of the technological competitiveness of Baz Biomedical’s patents.

Through this investment, Baz Biomedical plans to actively promote the excellence of next-generation solenoid-based needle-free drug delivery technology worldwide by strengthening domestic and international patent protection and pursuing aggressive overseas marketing.

A representative of Baz Biomedical stated, “2023 will be the inaugural year for Baz Biomedical to introduce its innovative needle-free drug delivery technology to the world, and NovoJet and CureJet will become icons of K-medical devices leading a new paradigm in the medical and beauty fields.”